Glycaemic and nonglycaemic effects of pioglitazone in triple oral therapy of patients with type 2 diabetes (original) (raw)
Management of cardiovascular risk factors with pioglitazone combination therapies in type 2 diabetes: an observational cohort study
Angel rodriguez
Cardiovascular Diabetology, 2011
View PDFchevron_right
Population Pharmacokinetics of Pioglitazone in South Indian Type-II Diabetic Patients
Devender Kodati
Asian Journal of Pharmaceutical and Clinical Research, 2014
View PDFchevron_right
Effects of Pioglitazone on Visceral Fat Metabolic Activity in Impaired Glucose Tolerance or Type 2 Diabetes Mellitus
Toshi Abe
The Journal of Clinical Endocrinology & Metabolism, 2013
View PDFchevron_right
Safety and efficacy of low dose pioglitazone compared with standard dose pioglitazone in type 2 diabetes with chronic kidney disease: A randomized controlled trial
Bancha Satirapoj
PLOS ONE, 2018
View PDFchevron_right
Comparative evaluation of Pioglitazone versus Voglibose on glycemic control in patients with Type 2 Diabetes Mellitus on Metformin
Mohd Faheem Mubeen
Journal of Medical Science And clinical Research, 2018
View PDFchevron_right
Pioglitazone reduces monocyte activation in type 2 diabetes
Simona Giubilato, Filippo Crea
2009
View PDFchevron_right
Pioglitazone: A Review of its Use in Type 2 Diabetes Mellitus
John Waugh, Dean Robinson
Drugs, 2006
View PDFchevron_right
Spotlight on Pioglitazone in Type 2 Diabetes Mellitus1
Dean Robinson, John Waugh
Treatments in Endocrinology, 2006
View PDFchevron_right
Combined Therapy of Pioglitazone and Atorvastatin Alleviate Diabetes in Rats More Effectively than That of Mono Therapy
saiful Islam
Pharmacology & Pharmacy, 2014
View PDFchevron_right
A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus
Meng Tan
Clinical Therapeutics, 2003
View PDFchevron_right
Addition of pioglitazone to stable insulin therapy in patients with poorly controlled type 2 diabetes: results of a double-blind, multicentre, randomized study
Jaime Davidson
Diabetes, Obesity and Metabolism, 2006
View PDFchevron_right
Effect of metformin and Pioglitazone on insulin dose reduction in type 2 diabetes mellitus patients: An open level comparative prospective study
Anindya Dasgupta
Journal of Diabetes Mellitus, 2012
View PDFchevron_right
Pioglitazone is Effective Therapy for Elderly Patients with Type 2 Diabetes Mellitus
Mehmood Khan
Drugs & Aging, 2004
View PDFchevron_right
Concomitant therapy with pioglitazone and insulin for the treatment of type 2 diabetes
Toshikazu Yamanouchi
Vascular Health and Risk Management, 2010
View PDFchevron_right
Efficacy and Safety of Pioglitazone Monotherapy in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomised Controlled Trials
Siew Hua Gan
View PDFchevron_right
Do We Still Need Pioglitazone for the Treatment of Type 2 Diabetes? A risk-benefit critique in 2013
Guntram Schernthaner
Diabetes Care, 2013
View PDFchevron_right
A review of pioglitazone HCL and glimepiride in the treatment of type 2 diabetes
Mozhgan Dorkhan
Vascular health and risk management, 2007
View PDFchevron_right
Comparison of glycaemic control over 1 year with pioglitazone or gliclazide in patients with Type 2 diabetes
Paolo Brunetti
Diabetic Medicine, 2006
View PDFchevron_right
Efficacy and Safety of PioglitazoneVersusMetformin in Patients with Type 2 Diabetes Mellitus: A Double-Blind, Randomized Trial
Guntram Schernthaner
The Journal of Clinical Endocrinology & Metabolism, 2004
View PDFchevron_right
Pioglitazone for the Treatment of Metabolic-Associated Fatty Liver Disease in People Living With HIV and Prediabetes
Supphamat Chirnaksorn
Cureus, 2021
View PDFchevron_right
Comparisons of Rosiglitazone Versus Pioglitazone Monotherapy Introduction and Associated Health Care Utilization in Medicaid-Enrolled Patients with Type 2 Diabetes Mellitus
Roger Anderson
Clinical Therapeutics, 2007
View PDFchevron_right
Comparison of Pioglitazone and Gliclazide in Sustaining Glycemic Control Over 2 Years in Patients With Type 2 Diabetes
Richard Urquhart
Diabetes Care, 2005
View PDFchevron_right
Efficacy and safety of generic and original pioglitazone in type 2 diabetes mellitus: a multicenter, a double-blinded, randomized-controlled study
S. Suwanwalaikorn
Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2010
View PDFchevron_right
Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study
Mark Kipnes
The American Journal of Medicine, 2001
View PDFchevron_right
Effect of Pioglitazone on Lipid Profile in Type 2 Diabetic Patients
MUHAMMAD BILAL
2012
View PDFchevron_right
Biochemical alterations and liver toxicity analysis with pioglitazone in healthy subjects
Md. Aftab Uddin
Drug and Chemical Toxicology, 2013
View PDFchevron_right
Pioglitazone Treatment Enlarges Subcutaneous Adipocytes in Insulin-Resistant Patients
Fred C. G. J. Sweep
The Journal of Clinical Endocrinology & Metabolism, 2009
View PDFchevron_right
Antiatherogenic Effect of Pioglitazone in Type 2 Diabetic Patients Irrespective of the Responsiveness to Its Antidiabetic Effect
Tetsuya Tagami
Diabetes Care, 2003
View PDFchevron_right